Literature DB >> 27334385

Aging in Fragile X Premutation Carriers.

Reymundo Lozano1, Naomi Saito2, Dallas Reed3, Marwa Eldeeb4, Andrea Schneider4, David Hessl5, Flora Tassone5,6, Laurel Beckett2, Randi Hagerman4.   

Abstract

It is now recognized that FMR1 premutation carriers (PC) are at risk to develop a range of neurological, psychiatric, and immune-mediated disorders during adulthood. There are conflicting findings regarding the incidence of hypertension, hypothyroidism, diabetes, and cancer in these patients that warrant further study. A retrospective controlled study was performed in a convenience sample of 248 controls (130 men, 118 women) and 397 FMR1 PC with and without fragile X-associated tremor ataxia syndrome (FXTAS) (176 men, 221 women); all participants were at least 45 years old (men: mean 62.4, SD 9.5; women: mean 62.8, SD 9.9; p = 0.63). Memory and cognitive assessments (Wechsler Adult Intelligence Scale (WAIS-III), Wechsler Memory Scale (WMS-III)) and molecular testing (CGG repeats and FMR1-mRNA levels) were performed. Additional data included body mass index (BMI), cholesterol levels, blood pressure, hemoglobin A1c (HbA1c) levels, and medical history. A higher percentage of PC subjects self-reported having a diagnosis of hypertension (50.0 vs. 35.0 %, p = 0.006) and thyroid problems (20.4 vs. 10.0 %, p = 0.012) than control subjects. When comparing controls versus PC with FXTAS, the association was higher for diabetes (p = 0.043); however, the effect was not significant after adjusting for demographic predictors. Blood pressure, blood glucose levels, HbA1c, and BMI values were not significantly different between the two groups. The PC with FXTAS group performed consistently lower in neuropsychological testing compared with the PC without FXTAS group, but the differences were very small for all but the WAIS full-scale IQ. Based on these findings, it appears that the risk for hypertension, thyroid problems, and diabetes may be more frequent in PC with FXTAS, which will require verification in future studies.

Entities:  

Keywords:  Ataxia; Cognition; FMR1; FXTAS; Fragile X syndrome; Premutation

Mesh:

Substances:

Year:  2016        PMID: 27334385      PMCID: PMC8020959          DOI: 10.1007/s12311-016-0805-x

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  36 in total

1.  Immune mediated disorders in women with a fragile X expansion and FXTAS.

Authors:  Isha Jalnapurkar; Nuva Rafika; Flora Tassone; Randi Hagerman
Journal:  Am J Med Genet A       Date:  2014-11-14       Impact factor: 2.802

Review 2.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

3.  Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS.

Authors:  F Tassone; C M Greco; M R Hunsaker; A L Seritan; R F Berman; L W Gane; S Jacquemont; K Basuta; L-W Jin; P J Hagerman; R J Hagerman
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

4.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

5.  Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome.

Authors:  Weerasak Chonchaiya; Flora Tassone; Paul Ashwood; David Hessl; Andrea Schneider; Luis Campos; Danh V Nguyen; Randi J Hagerman
Journal:  Hum Genet       Date:  2010-09-01       Impact factor: 4.132

6.  Fragile X syndrome and acute lymphoblastic leukemia.

Authors:  M Cunningham; J D Dickerman
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

7.  Phenobarbital use and neurological problems in FMR1 premutation carriers.

Authors:  Wilmar Saldarriaga; Pamela Lein; Laura Yuriko González Teshima; Carolina Isaza; Lina Rosa; Andrew Polyak; Randi Hagerman; Santhosh Girirajan; Marisol Silva; Flora Tassone
Journal:  Neurotoxicology       Date:  2016-01-21       Impact factor: 4.294

8.  Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.

Authors:  Jonathan Polussa; Andrea Schneider; Randi Hagerman
Journal:  Brain Disord Ther       Date:  2014

Review 9.  The cognitive neuropsychological phenotype of carriers of the FMR1 premutation.

Authors:  Jim Grigsby; Kim Cornish; Darren Hocking; Claudine Kraan; John M Olichney; Susan M Rivera; Andrea Schneider; Stephanie Sherman; Jun Yi Wang; Jin-Chen Yang
Journal:  J Neurodev Disord       Date:  2014-07-30       Impact factor: 4.025

10.  The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation.

Authors:  Rossella Lucá; Michele Averna; Francesca Zalfa; Manuela Vecchi; Fabrizio Bianchi; Giorgio La Fata; Franca Del Nonno; Roberta Nardacci; Marco Bianchi; Paolo Nuciforo; Sebastian Munck; Paola Parrella; Rute Moura; Emanuela Signori; Robert Alston; Anna Kuchnio; Maria Giulia Farace; Vito Michele Fazio; Mauro Piacentini; Bart De Strooper; Tilmann Achsel; Giovanni Neri; Patrick Neven; D Gareth Evans; Peter Carmeliet; Massimiliano Mazzone; Claudia Bagni
Journal:  EMBO Mol Med       Date:  2013-09-16       Impact factor: 12.137

View more
  7 in total

1.  Tremor-Ataxia syndrome and primary ovarian insufficiency in an FMR1 premutation carrier.

Authors:  Wilmar Saldarriaga-Gil; Tatiana Rodriguez-Guerrero; Andres Fandiño-Losada; Julian Ramirez-Cheyne
Journal:  Colomb Med (Cali)       Date:  2017-09-30

2.  Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer's Disease.

Authors:  Elber Yuksel Aydin; Andrea Schneider; Dragana Protic; Jun Yi Wang; Veronica Martínez-Cerdeño; Flora Tassone; Hiu-Tung Tang; Susan Perlman; Randi J Hagerman
Journal:  Clin Interv Aging       Date:  2020-02-26       Impact factor: 4.458

3.  Fragile X premutation carrier screening in Pakistani preconception women in primary care consultation.

Authors:  Neelam Meraj; Muhammad Yasin; Zia Ur Rehman; Haleema Tahir; Humaira Jadoon; Niamat Khan; Rabia Shahid; Maria Zubair; Irba Zulfiqar; Musarrat Jabeen; Shahzadi Neelam; Abdul Hameed; Shamim Saleha
Journal:  BMC Womens Health       Date:  2022-03-04       Impact factor: 2.809

4.  The effect of college degree attainment on neurodegenerative symptoms in genetically at-risk women.

Authors:  Jinkuk Hong; Robert S Dembo; Leann Smith DaWalt; Murray Brilliant; Elizabeth M Berry-Kravis; Marsha Mailick
Journal:  SSM Popul Health       Date:  2022-10-05

Review 5.  Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders.

Authors:  Indhu-Shree Rajan-Babu; Samuel S Chong
Journal:  Genes (Basel)       Date:  2016-10-14       Impact factor: 4.096

6.  Characterization of the Metabolic, Clinical and Neuropsychological Phenotype of Female Carriers of the Premutation in the X-Linked FMR1 Gene.

Authors:  Eleonora Napoli; Yingratana Amabel McLennan; Andrea Schneider; Flora Tassone; Randi J Hagerman; Cecilia Giulivi
Journal:  Front Mol Biosci       Date:  2020-10-22

7.  Evidence for Three Subgroups of Female FMR1 Premutation Carriers Defined by Distinct Neuropsychiatric Features: A Pilot Study.

Authors:  Lauren M Schmitt; Kelli C Dominick; Rui Liu; Ernest V Pedapati; Lauren E Ethridge; Elizabeth Smith; John A Sweeney; Craig A Erickson
Journal:  Front Integr Neurosci       Date:  2022-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.